Based on the structure and function of the HOTAIR, we targeted to establish a structure-based methodology by abrogating HOTAIR/EZH2 interactions and identify a lead compound of HOTAIR by binding at micro-domain 36G46A, thereby benefiting these glioma and breast cancer patients with high levels of HOTAIR and EZH2. This evidence concerns the gene EZH2 and central nervous system cancer.